Abbonarsi

Worse fibro-inflammatory activity on diagnostic liver biopsy adversely impacts biochemical remission in autoimmune hepatitis - 07/08/24

Doi : 10.1016/j.clinre.2024.102442 
Pooja Khonde a, Shelley Choudhury b, Nicholas C Spies a, Nadia Naz c, Janis Stoll b, Jaquelin Fleckenstein d, Mai He a, Samuel Ballentine a, Sakil Kulkarni b,
a Department of Pathology and Immunology, Washington University in St. Louis, MO, USA 
b Department of Pediatrics, Washington University in St. Louis, MO, USA 
c Department of Pediatrics, University of Iowa, Iowa City, IA, USA 
d Department of Internal Medicine, Washington University in St. Louis, MO, USA 

Corresponding author at: Department of Pediatrics, Division of Gastroenterology, Hepatology and Nutrition, Washington University School of Medicine, 660 S. Euclid Ave, St. Louis, 63110, Missouri, USA.Department of PediatricsDivision of GastroenterologyHepatology and NutritionWashington University School of Medicine660 S. Euclid Ave, St. LouisMissouri63110USA

Highlights

Achieving biochemical remission in patients with autoimmune hepatitis prevents progression to end stage liver disease.
A review of the pre-treatment liver biopsy slides for pediatric and adult patients with autoimmune hepatitis was conducted by three pathologists blinded to clinical information.
Findings of advanced fibrosis on diagnostic liver biopsy of patients with autoimmune hepatitis was accompanied by more pronounced necro-inflammatory activity, lower platelet levels and higher serum immunoglobulin G levels.
Advanced fibrosis on diagnostic liver biopsy translated to lower rates of biochemical remission during the first year after diagnosis.
Pediatric age at diagnosis and advanced fibrosis on diagnostic liver biopsy were associated with higher steroid exposure at 1 year post diagnosis.

Il testo completo di questo articolo è disponibile in PDF.

Abstract

Background

Autoimmune hepatitis (AIH) patients can present with advanced fibrosis at diagnosis or may progress to the same if biochemical remission on treatment is not achieved.

Methods

We conducted a single-center retrospective analysis of 34 pediatrics and 39 adult AIH patients. Three pathologists, blinded to clinical information, reviewed the diagnostic liver biopsy (DLB) slides of AIH patients. We evaluated the impact of clinical, laboratory, and histopathologic parameters on outcomes including biochemical remission (BR).

Results

Incidence of advanced (Ludwig stage 3 or 4) fibrosis on DLB was 45.2 %. AIH patients with advanced fibrosis had higher median Ishak score (p < 0.001) and higher IgG level (p = 0.01) at diagnosis. The incidence of BR at 6-month (31.2% vs. 88.6 %, p = 0.001) and 1-year (68.8% vs. 88.6 %, p = 0.04) post-diagnosis was significantly lower in AIH patients with advanced fibrosis. Although not statistically significant, a higher proportion of AIH patients with advanced fibrosis were on high dose of steroids (58% vs. 37.9 %, p = 0.1) at 1 year post diagnosis. Higher serum IgG level at diagnosis was associated with lower odds of achieving BR at 6-month (p = 0.004) and 1-year (p = 0.03) post-diagnosis in multivariate analysis. Pediatric age at diagnosis (p = 0.02) was associated with higher steroid dose at 1-year post-diagnosis in univariate analysis.

Conclusions

Findings of advanced fibrosis on DLB of AIH patients was accompanied by more pronounced necro-inflammatory activity and higher serum IgG level, which translated to lower rates of BR and higher exposure to steroids during the first year after diagnosis.

Il testo completo di questo articolo è disponibile in PDF.

Keywords : Autoimmune hepatitis, Biochemical remission, Fibrosis, Platelet count, Immunoglobulin G


Mappa


© 2024  Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 48 - N° 8

Articolo 102442- Ottobre 2024 Ritorno al numero
Articolo precedente Articolo precedente
  • Biomarker for infection in children with decompensated chronic liver disease: Neutrophilic CD64 or procalcitonin?
  • Vignesh Vinayagamoorthy, Anshu Srivastava, Anamika Kumari Anuja, Vikas Agarwal, Rungmei Marak, Moinak Sen Sarma, Ujjal Poddar, Surender Kumar Yachha
| Articolo seguente Articolo seguente
  • Laparoscopic anatomical right hepatectomy using a four-incision anterior approach: Technical details and surgical outcomes (with Video)
  • Cong Liu, Haoling Liu, Maria A. Parra, Le Qi, Qingquan Bai, Jiashu Zou, Qian Cao, Xianbo Shen, Haiyan Yang

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2025 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.